Innorna Shortlisted for 2026 Prix Galien Best Startup Award

The nomination centers on the company’s progress with its lead program, IN026. This mRNA therapy, intended to treat refractory gout by reducing uric acid levels, received FDA clearance for clinical trials in March 2026. By focusing on chronic disease rather than traditional vaccine applications, Innorna has positioned itself among the industry's most innovative emerging players.

The Prix Galien, often described as the Nobel Prize of biopharmaceuticals, recognizes medical breakthroughs that significantly improve patient outcomes. A panel of global scientists and industry leaders will select the final winners, with the results to be unveiled on October 29 at the American Museum of Natural History in New York City.

Founder and CEO Dr. Linxian Li stated that the nomination validates years of platform engineering. The company currently manages a library of over 6,000 chemically diverse ionizable lipids and has secured $150 million in total funding to date to support its vertically integrated development pipeline.